Process and analytical insights for GMP manufacturing of mRNA lipid nanoparticles

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Process and analytical insights for GMP manufacturing of mRNA lipid nanoparticles

The successful development and rapid deployment of the messenger RNA (mRNA) vaccines against SARS-CoV-2 virus has catalyzed the industry to look more closely at the technology beyond its potential use for novel vaccines to enable breakthrough treatments for cancer, rare diseases, and more. However, the absence of standardized protocols means manufacturers must develop and optimize their process, leading to a considerable number of variables and decisions throughout the production workflow.

This webinar will discuss key insights into the potential of the mRNA and lipid nanoparticle (LNP) technologies that underpin the COVID-19 vaccines, barriers to successful industrialized manufacture of mRNA–LNPs, and approaches to optimizing process development and manufacturing. The panel will address:

The 5 steps of manufacturing mRNA-LNP drug products, including DNA template manufacturing, mRNA drug substance synthesis and purification, mRNA–LNP formulation and purification, fill/finish operations, and analytical testing
Process and analytical considerations for GMP manufacturing of mRNA-LNPs
Challenges and opportunities for mRNA-LNP therapeutic development

Emmanuelle Cameau

Gene Therapy Strategic Technology Partnership Leader EMEA Pall Corporation

Emmanuelle Cameau is a Senior Bioreactor Applications Scientist within the Scientific Laboratory Services (SLS) at Pall Biotech. Highly skilled in the field of cell culture applications and with 10+ years of experience, Emmanuelle previously held positions as a Bioprocess Specialist at Pall, and a Biotech Process Sciences Upstream Process Development Engineer at Merck Serono. She received her Biotechnology Engineer diploma from the former Ecole Supérieure d’Ingénieurs de Luminy (now Polytech Marseille).